Class II · Moderate risk Terminated
Progesterone 50 mg capsules
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
FDA Drug Recalls
17,898 recalls, newest first
Class II · Moderate risk Terminated
Progesterone 200 mg Troche
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Naltrexone 4.5 mg capsule
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Magic Bullet Supplement
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Liothyronine
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Liothyronine
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Lidocaine/Priloc/PE 30/5/0.25% 30 GM jars
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Lidocaine/Priloc/PE 15/5/0.25% 30 GM jars
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
Finasteride/Biotin 1 mg/50 mcg
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class II · Moderate risk Terminated
DHEA/Pregnenol One 10.25 MG Cap
Reason Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
Class I · High risk Terminated
Ketorolac Tromethamine Injection
Reason Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
Class II · Moderate risk Terminated
Ketorolac Tromethamine Injection
Reason Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
Class I · High risk Terminated
Panther Platinum 30000 Capsules
Reason Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Class I · High risk Terminated
Rhino 7 Platinum 30000 Capsules
Reason Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Class I · High risk Terminated
Stallion Platinum 30000 Capsules in blue
Reason Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Class I · High risk Terminated
Bull Platinum 30000 Capsules
Reason Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 150 mg Rx Only 500 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 300 mg Rx Only 250 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 300 mg Rx Only 100 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 150 mg Rx Only 100 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Ongoing
Glenmark Ranitidine Tablets USP 150 mg Rx Only 60 Tablets…
Reason CGMP Deviations: Presence of NDMA impurity detected in product.
Class II · Moderate risk Terminated
Hydrocortisone and Acetic Acid Otic Solution
Reason Subpotent Drug: Low Out of specification (OOS) assay results for the hydrocortisone portion of this product.
Class III · Low risk Terminated
NORepinephrine Bitartrate 4 mg added to 250 mL 5% Dextrose Injection USP
Reason Subpotent Drug
Class III · Low risk Terminated
NORepinephrine Bitartrate 8 mg added to 500 mL 5% Dextrose Injection USP
Reason Subpotent Drug